-transparent.png){kind=logo}
After a drug-free period of 1 week following 2 weeks of haloperidol treatment, the increased response of striatal 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) to a challenge dose of haloperidol was significantly reduced. Tolerance to this effect was not, however, seen in the mesolimbic system. Pretreatment of the rats with methamphetamine (MAP) for 8 days prior to chronic haloperidol significantly enhanced the DOPAC and HVA increase produced by the challenge with haloperidol in both brain areas. The reduced response of striatal DOPAC or HVA after chronic haloperidol was prevented by pretreatment with MAP. The data suggest that the long-term dopamine receptor stimulation induced by MAP may antagonize the tolerance produced by chronic haloperidol treatment.
M Toru, and
N Mataga, and
M Takashima, and
T Nishikawa
April 1977,
Pharmacological research communications,
M Toru, and
N Mataga, and
M Takashima, and
T Nishikawa
February 1986,
European journal of pharmacology,
M Toru, and
N Mataga, and
M Takashima, and
T Nishikawa
January 1979,
Archives internationales de pharmacodynamie et de therapie,
M Toru, and
N Mataga, and
M Takashima, and
T Nishikawa
February 1980,
Journal of pharmacobio-dynamics,
M Toru, and
N Mataga, and
M Takashima, and
T Nishikawa
December 1974,
Life sciences,
M Toru, and
N Mataga, and
M Takashima, and
T Nishikawa
December 1985,
Life sciences,
M Toru, and
N Mataga, and
M Takashima, and
T Nishikawa
February 1980,
Life sciences,
M Toru, and
N Mataga, and
M Takashima, and
T Nishikawa
January 1978,
European journal of pharmacology,
M Toru, and
N Mataga, and
M Takashima, and
T Nishikawa
June 1979,
European journal of pharmacology,
M Toru, and
N Mataga, and
M Takashima, and
T Nishikawa
September 1976,
European journal of pharmacology,
